Spero Therapeutics (SPRO) Gains from Investment Securities (2016 - 2026)
Quarterly Gains from Investment Securities fell 57.71% to $1.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Mar 2026, down 57.71% year-over-year, with the annual reading at $2.4 million for FY2025, 14.72% down from the prior year.
Spero Therapeutics filings provide 11 years of Gains from Investment Securities readings, the most recent being $1.1 million for Q1 2026.
- Gains from Investment Securities hit $1.1 million in Q1 2026 for Spero Therapeutics, down from $2.4 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $5.8 million in Q1 2022 and bottomed at $35604.0 in Q1 2024.
- Average Gains from Investment Securities over 5 years is $1.8 million, with a median of $1.1 million recorded in 2026.
- The largest annual shift saw Gains from Investment Securities crashed 99.11% in 2024 before it soared 7327.76% in 2025.
- Spero Therapeutics' Gains from Investment Securities stood at $100000.0 in 2022, then skyrocketed by 2111.0% to $2.2 million in 2023, then increased by 27.31% to $2.8 million in 2024, then fell by 14.72% to $2.4 million in 2025, then tumbled by 53.41% to $1.1 million in 2026.
- Per Business Quant, the three most recent readings for SPRO's Gains from Investment Securities are $1.1 million (Q1 2026), $2.4 million (Q4 2025), and $414417.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Spero Therapeutics | 154.37 Mn | 98.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.12 Mn |
| Mar 31, 2026 | 1.12 Mn |
| Dec 31, 2025 | 2.40 Mn |
| Dec 31, 2025 | 2.40 Mn |
| Sep 30, 2025 | 414,417.00 |
| Sep 30, 2025 | 414,417.00 |
| Jun 30, 2025 | 230,932.00 |
| Jun 30, 2025 | 230,932.00 |
| Mar 31, 2025 | 2.64 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Dec 31, 2024 | 2.81 Mn |
| Dec 31, 2024 | 2.81 Mn |
| Sep 30, 2024 | 35,604.00 |
| Sep 30, 2024 | 35,604.00 |
| Jun 30, 2024 | 35,604.00 |
| Jun 30, 2024 | 35,604.00 |
| Mar 31, 2024 | 35,604.00 |
| Mar 31, 2024 | 35,604.00 |
| Dec 31, 2023 | 2.21 Mn |
| Dec 31, 2023 | 2.21 Mn |
| Sep 30, 2023 | 1.11 Mn |
| Sep 30, 2023 | 1.11 Mn |
| Jun 30, 2023 | 3.73 Mn |
| Jun 30, 2023 | 3.73 Mn |
| Mar 31, 2023 | 4.00 Mn |
| Mar 31, 2023 | 4.00 Mn |
| Dec 31, 2022 | 100,000.00 |
| Dec 31, 2022 | 100,000.00 |
| Sep 30, 2022 | 140,000.00 |
| Sep 30, 2022 | 140,000.00 |
| Jun 30, 2022 | 4.62 Mn |
| Jun 30, 2022 | 4.62 Mn |
| Mar 31, 2022 | 5.78 Mn |
| Mar 31, 2022 | 5.78 Mn |
| Dec 31, 2021 | 4.89 Mn |
| Dec 31, 2021 | 4.89 Mn |
| Sep 30, 2021 | 1.51 Mn |
| Sep 30, 2021 | 1.51 Mn |
| Jun 30, 2021 | 4.58 Mn |
| Jun 30, 2021 | 4.58 Mn |
| Mar 31, 2021 | 1.02 Mn |
| Mar 31, 2021 | 1.02 Mn |
| Dec 31, 2020 | 3.68 Mn |
| Dec 31, 2020 | 3.68 Mn |
| Sep 30, 2020 | 980,828.00 |
| Sep 30, 2020 | 980,828.00 |
| Jun 30, 2020 | 82,623.00 |
| Jun 30, 2020 | 82,623.00 |
| Mar 31, 2020 | 3.65 Mn |
| Mar 31, 2020 | 3.65 Mn |
| Sep 30, 2019 | 3.00 Mn |
| Sep 30, 2019 | 3.00 Mn |
| Jun 30, 2019 | 100,000.00 |
| Jun 30, 2019 | 100,000.00 |
| Mar 31, 2019 | 1,000.00 |
| Mar 31, 2019 | 1,000.00 |
| Dec 31, 2018 | 2.30 Mn |
| Dec 31, 2018 | 2.30 Mn |
| Sep 30, 2018 | 476,711.00 |
| Sep 30, 2018 | 476,711.00 |
| Jun 30, 2018 | 277,038.00 |
| Jun 30, 2018 | 277,038.00 |
| Mar 31, 2018 | 567,319.00 |
| Mar 31, 2018 | 567,319.00 |
| Dec 31, 2017 | 2.01 Mn |
| Dec 31, 2017 | 2.01 Mn |
| Sep 30, 2017 | 243,942.00 |
| Sep 30, 2017 | 243,942.00 |
| Dec 31, 2016 | 159,890.00 |
| Dec 31, 2016 | 159,890.00 |